Table 1.
Probiotic bacteria used in the trial and their properties.
| Probiotic strains (Zheng et al, 2020) | Surface characteristics | Production of antagonistic compounds | EPS | |||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Autoaggregation | Hydrophobicity | Pathogen inhibition | H2O2 | Lactic acid (g/L) | ||
| Lactobacillus johnsonii CRL1693 | High | High |
Escherichia coli 3511AD Salmonella Dublin MP/07 Staphylococcus aureus MP/0 |
Low | 10.56 | + |
| Ligilactobacillus murinus CRL1695 | High | Low | Salmonella Typhimurium MP/08 | Low | 6.38 | – |
| Limosilactobacillus mucosae CRL1696 | Low | Low | Not determined | High | 5.70 | – |
| Ligilactobacillus salivarium CRL1702 | Low | Medium | Salmonella Typhimurium MP/08 | Low | 8.12 | – |
EPS — Extracellular polymeric substances.